fadrozole

Fadrozole is a nonsteroidal aromatase inhibitor with potential antineoplastic activity(IC50 : 6.4 nM)

Fadrozole hydrochloride (CGS 16949A) is a model aromatase inhibitor that effectively suppresses estrogen production in fish ovaries.

Fadrozole is a selective aromatase inhibitor used effectively in the treatment of estrogen-dependent conditions, such as breast cancer.

(R)-Fadrozole ((R)-CGS 16949A; FAD286) is a potent nonsteroidal inhibitor. (R)-Fadrozole also inhibits human placental aromatase (pIC 50 = 6.17) and aldosterone biosynthesis. (R)-Fadrozole reverses cardiac fibrosis in spontaneously hypertensive heart failure rats..

Fadrozole is a selective inhibitor of aromatase. It also effective in the treatment of estrogen-dependent diseases including breast cancer.

(S)-Dexfadrostat ((S)-Fadrozole), an aromatase inhibitor, exhibits an IC 50 of 4.6 nM in in vitro assays using human placental microsomes. It is applicable for research on estrogen-dependent breast cancer, gynecomastia, and systemic lupus erythematosus.

Dexfadrostat is an effective non-steroidal inhibitor of aldosterone synthase (CYP 11B2).